Deutetrabenazine for the treatment of Huntington’s chorea

References

• Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83–98.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Roos RAC. Chorea associated with Huntington’s disease: to treat or not to treat? Mov. Disord. 2014;29:1414–1418.
   PubMed Web of Science ®Google Scholar
• Jacobs M, Hart EP, Van Zwet EW, et al. Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study. J Neurol. 2016;263:2080–2085.
   PubMed Web of Science ®Google Scholar
• DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64:20–24.
   PubMedGoogle Scholar
• Cardoso F, Seppi K, Mair KJ, et al. Seminar on choreas. Lancet Neurol. 2006;5:589–602.
   PubMed Web of Science ®Google Scholar
• Wyant KJ, Ridder AJ, Dayalu P. Huntington’s disease-update on treatments. Curr Neurol Neurosci Rep. 2017;17:33.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–372.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Vijayakumar D, Jankovic J. Drug-Induced dyskinesia, part 2: treatment of tardive dyskinesia. Drugs. 2016;76:779–787.
   PubMed Web of Science ®Google Scholar
• Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet. Mov. (N. Y). 2013;3:1–11.
   Google Scholar
• Chen JJ, Ondo WG, Dashtipour K, et al. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487–1504.
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193–197.
   PubMed Web of Science ®Google Scholar
• Eliasen A, Dalhoff KP, Horwitz H. Neurological diseases and risk of suicide attempt: a case-control study. J Neurol. 2018;265:1303–1309.
   PubMed Web of Science ®Google Scholar
• Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD investigators. BMC Neurol. 2009;9:62.
   PubMed Web of Science ®Google Scholar
• Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? . Clin Neuropharmacol. 2006;29:259–264.
   PubMed Web of Science ®Google Scholar
• Heo Y-A, Scott LJ. Deutetrabenazine: A review in chorea associated with Huntington’s disease. Drugs. 2017;77:1857–1864.
   PubMed Web of Science ®Google Scholar
• Mehanna R, Hunter C, Davidson A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28:210–215.
   PubMed Web of Science ®Google Scholar
• Reilmann R. Deutetrabenazine-not a revolution but welcome evolution for treating chorea in Huntington disease. JAMA Neurol. 2016;73:1404–1406.
   PubMed Web of Science ®Google Scholar
• Halford B. Deuterium switcheroo breathes life into old drugs. Chem Eng News. 2016;94:32–36.
   Web of Science ®Google Scholar
• Schmidt C. First deuterated drug approved. Nat Biotechnol. 2017;35:493–494.
   PubMed Web of Science ®Google Scholar
• Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78:525–541.
   PubMed Web of Science ®Google Scholar
• Belleau B, Burba J, Pindell M, et al. Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science. 1961;133:102–104.
   PubMed Web of Science ®Google Scholar
• Schneider F, Erisson L, Beygi H, et al. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/Carbidopa (CD) compared to L-DOPA/CD following single oral dose administration in healthy subjects. Br J Clin Pharmacol. 2018. doi:10.1111/bcp.13702.
   Google Scholar
• Timmins GS. Deuterated drugs; updates and obviousness analysis. Expert Opin Ther Pat. 2017;27:1353–1361.
   PubMed Web of Science ®Google Scholar
• Mullard A. Deuterated drugs draw heavier backing. Nat Rev Drug Discov. 2016;15:219–221.
   PubMed Web of Science ®Google Scholar
• DeWitt SH, Maryanoff BE. Deuterated drug molecules: focus on FDA-approved deutetrabenazine. Published as part of the biochemistry series “biochemistry to bedside”. Biochemistry. 2018;57:472–473.
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Paras N. Deutetrabenazine for treatment of chorea in Huntington disease. JAMA. 2016;316:33–35.
   PubMed Web of Science ®Google Scholar
• Teva. Pharmaceuticals USA Inc. AUSTEDO (deutetrabenazine): US prescribing information. http://www.fda.gov. 2017. Accessed on 14 May 2018.
   Google Scholar
• Paton DM. Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome. Drugs Today (Barc). 2017;53:89–102.
   PubMed Web of Science ®Google Scholar
• Dean M, Sung V. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease. Drug Des Devel Ther. 2018;12:313–319.
   PubMed Web of Science ®Google Scholar
• Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother. 2018;18:51–63.
   PubMed Web of Science ®Google Scholar
• Frank S, Testa CM, Stamler D, et al., Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316:40–50.
   PubMed Web of Science ®Google Scholar
• Frank S, Vaughan C, Stamler C, et al. The long-term safety of deutetrabenazine for chorea in Huntington disease: a preliminary analysis. Mov Disord. 2017;(Suppl 2). Abstract no. 468. Accessed from: http://www.mdsabstracts.org/abstract/the-long-term-safety-of-deutetrabenazine-for-chorea-in-huntington-disease/.
   Google Scholar
• Carroll JB, Bates GP, Steffan J, et al. Treating the whole body in Huntington’s disease. Lancet Neurol. 2015;14:1135–1142.
   PubMed Web of Science ®Google Scholar
• Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74:977–982.
   PubMed Web of Science ®Google Scholar
• Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4:3.
   PubMedGoogle Scholar
• Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine (p07.210). Neurology. 2013;80:P07.210.
   Web of Science ®Google Scholar
• Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Psychiatry. 2017;4:595–604.
   PubMed Web of Science ®Google Scholar
• Stamler D, Offman E, Bradbury M, et al. A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of sd-809 (deutetrabenazine) and tetrabenazine on the corrected qt interval (p2.347). Neurology. 2016;86. Accessed from: http://n.neurology.org/content/86/16_Supplement/P2.347.
   Google Scholar
• Hauser RA, Truong D. Tardive dyskinesia: out of the shadows. J Neurol Sci. 2018;389:1–3.
   PubMed Web of Science ®Google Scholar
• Rodrigues FB, Duarte GS, Costa J, et al. tetrabenazine versus deutetrabenazine for Huntington’s disease: twins or distant cousins? . Mov Disord Clin Pract. 2017;4:582–585.
   PubMed Web of Science ®Google Scholar